Merck's Branded Generics Will Play A Supplementary, Country-specific Role
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Merck is putting into play a branded generics business strategy that involves extracting value out of a large set of its off-patented drugs through an aggressive push into developing markets, where the "lifecycle value of its brands" is significantly higher as compared to developed markets
You may also be interested in...
Post-merger MSD To Begin Rollout Of Merck and Schering-Plough Legacy Products In Japan
TOKYO - Merck, previously operating in Japan via majority-held Banyu Pharmaceutical, will merge with Schering-Plough Japan Oct. 1 under the new title MSD; the combined company expects to vault into the rankings of the top three pharmaceutical firms in Japan thanks to constant rollout of new products in the near-term future
Post-merger MSD To Begin Rollout Of Merck and Schering-Plough Legacy Products In Japan
TOKYO - Merck, previously operating in Japan via majority-held Banyu Pharmaceutical, will merge with Schering-Plough Japan Oct. 1 under the new title MSD; the combined company expects to vault into the rankings of the top three pharmaceutical firms in Japan thanks to constant rollout of new products in the near-term future
"We Want To Shape Up Medical Treatment Paradigm Through Partnerships," Says Merck Asia-Pac President Ramesh Subrahmanian: An Interview With PharmAsia News (Part 2 of 2)
Merck Asia Pacific President of Human Health Ramesh Subrahmanian has been among the most energetic executives to have worked in the Indian pharmaceutical industry. Prior to serving in his present responsibilities, Subrahmanian worked for Sanofi-Aventis in several senior capacities - one of which was to head the company's Indian operations in 2000.